Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cantargia in connection with the sale of immunology program CAN10
Mandate

Vinge advises Cantargia in connection with the sale of immunology program CAN10

July 21, 2025

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.

Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment, and Cantargia is eligible to up to an additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales.

The Vinge team includes Sofie Nordgren, Christian Lindhé, Martin Madsen Svanberg and Carolina Lundh.

Related

Vinge has advised Acrinova in connection with voluntary share redemption offering

 Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Lejon Entreprenad

 Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Lejon Entreprenad, a well-established specialist company offering qualified services within surface treatment, including industrial painting, anti-corrosion painting, and FROSIO inspections.
October 27, 2025

Vinge has advised Ingka Investments on its largest forestland acquisition

 Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025